3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2/3
1
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Neoplasms
2
Rectal Neoplasms
1
Pain
1
Neoplasm Metastasis
1
Multiple Endocrine Neoplasia Type 1
1
Colorectal Neoplasms
1
Cancer Pain
1
Interventions
Gemcitabine
5
Capecitabine
4
pembrolizumab
3
Fluorouracil
3
Cisplatin
3
vinflunine
2
enzalutamide
2
cabazitaxel
2
abiraterone
2
Ipilimumab
2
Haloperidol
2
Androgen Antagonists
2
vedolizumab
1
trifluridine tipiracil drug combination
1
relugolix
1
racemetyrosine
1
nimotuzumab
1
nilutamide
1
lanreotide
1
histrelin
1
futibatinib
1
exemestane
1
dexamethasone acetate
1
dexamethasone 21-phosphate
1
bicalutamide
1
beta-Glucans
1
auricularum
1
atezolizumab
1
apatinib
1
apalutamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Neoplasm Metastasis
×
Water
×
Clear all
NCT07321847
2026-01-07
INJECTABL-3
Immunophotonics, Inc.
Phase 2/3
Not yet recruiting
717 enrolled